Bengaluru-based biopharmaceutical company PlasmaGen Biosciences has secured ₹150 crore in a new funding round led by ViNS Bioproducts, with participation from pharmaceutical entrepreneurs, family offices, high-net-worth individuals, and existing investors. The funding has pushed the company’s valuation to over ₹1,500 crore, reflecting strong investor confidence in India’s plasma-derived therapeutics market.
With this round, PlasmaGen’s cumulative fundraising has crossed ₹600 crore. The capital comes at a strategic moment as the company scales its manufacturing footprint and prepares for expansion beyond domestic markets.
Strengthening India’s Plasma-Derived Therapies Ecosystem
Founded in 2010, PlasmaGen Biosciences focuses on the development and manufacturing of plasma-derived medicines that are critical for treating immune deficiencies, bleeding disorders, liver conditions, and neurological diseases. Products such as immunoglobulins, albumin, clotting factors, and anti-D immunoglobulin are widely used in hospitals and specialised care centres.
India has long depended on imports for these complex therapies, which often results in supply constraints and higher treatment costs. PlasmaGen aims to change this by building domestic capabilities, improving access to essential therapies while supporting India’s broader goal of healthcare self-reliance.
Kolar Facility Drives Manufacturing Scale-Up
A key milestone in PlasmaGen’s journey has been the commissioning of its plasma fractionation facility in Kolar, Karnataka, which became commercially operational in late 2023. This facility is among the limited number of private-sector plasma fractionation plants in the country and plays a crucial role in strengthening local production.
The Kolar unit enables PlasmaGen to process plasma at scale and improve the availability of life-saving medicines within India. It also reduces reliance on overseas suppliers and supports stable supply chains for hospitals and healthcare providers.
Expansion Plans and Long-Term Vision
The newly raised funds will be used to accelerate international expansion, with the company exploring regulatory approvals and distribution partnerships in select global markets. PlasmaGen also plans to expand its product portfolio by introducing additional plasma-derived therapies to address unmet medical needs.
Alongside growth initiatives, the company will invest in leadership, operational efficiency, and manufacturing infrastructure to support sustainable scale. Backed by investors such as Eight Roads Ventures, F-Prime Capital, and FIL Capital Investments, PlasmaGen Biosciences is positioning itself as a key player in India’s evolving biopharmaceutical landscape.
As demand for specialised biological therapies continues to grow, PlasmaGen’s latest funding round marks an important step towards building a resilient, self-reliant, and globally competitive plasma therapeutics ecosystem in India.